Citation Impact
Citing Papers
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
2011 Standout
Identification of a Primary Target of Thalidomide Teratogenicity
2010 StandoutScience
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
2005 StandoutScience
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
2010
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
2004 Standout
Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.
2002
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
2004 Standout
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
2009 Standout
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
2001
Multiple myeloma associated with diffuse osteosclerotic bone lesions: A clinical entity distinct from osteosclerotic myeloma (POEMS syndrome)
1997
An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus.
1992
Mechanisms, regulation and functions of the unfolded protein response
2020 Standout
PROGNOSTIC FACTORS IN MULTIPLE MYELOMA
1999
Clinical translation of angiogenesis inhibitors
2002 Standout
Clinical Course of Patients With Relapsed Multiple Myeloma
2004
HIF-1: Using Two Hands to Flip the Angiogenic Switch
2000 StandoutNobel
High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma.
1994
Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells
1999 Standout
Tumor angiogenesis: past, present and the near future
2000
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
2004 Standout
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
1996 Standout
Angiogenesis: an organizing principle for drug discovery?
2007 Standout
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways
2005 StandoutNobel
Vascular Endothelial Growth Factor and Angiogenesis
2004 Standout
Angiogenesis in cancer and other diseases
2000 StandoutNature
The biology of VEGF and its receptors
2003 Standout
Putting tumours in context
2001 Standout
Cancer genes and the pathways they control
2004 Standout
Current Therapy for Multiple Myeloma
2002
Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component
2009
Angiogenesis-dependent diseases
2001
STATs in oncogenesis
2000 Standout
B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules
2002
Immunity, Inflammation, and Cancer
2010 Standout
Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation
2001
VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment
2004 Standout
pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels
2014 Standout
Thalidomide in multiple myeloma: lack of response of soft‐tissue plasmacytomas
2001
Thalidomide in the Treatment of Relapsed Multiple Myeloma
2000
Capturing complex 3D tissue physiology in vitro
2006 Standout
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
2008
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
2003 Standout
Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials
2001
Applications of machine learning in drug discovery and development
2019 Standout
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
1999 Standout
The Ki-67 protein: From the known and the unknown
2000 Standout
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
2002 Standout
Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination With Bortezomib for Multiple Myeloma: Effects of Adverse Prognostic Factors on Outcome
2011
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Pro-angiogenic Activities of CYR61 (CCN1) Mediated through Integrins αvβ3 and α6β1 in Human Umbilical Vein Endothelial Cells
2002 Standout
New functions for the matrix metalloproteinases in cancer progression
2002 Standout
Angiogenesis as a therapeutic target
2005 StandoutNature
Tumor Angiogenesis
2008 Standout
Increased serum levels of β2m‐free HLA class I heavy chain in multiple myeloma
1999
The dawning era of polymer therapeutics
2003 Standout
Tumorigenesis and the angiogenic switch
2003 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process
1998
Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation.
2001
Maturation of the hemostatic system during childhood
1992 Standout
Angiogenesis Research: Guidelines for Translation to Clinical Application
2001
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
2004 Standout
The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells
2005 Standout
Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma [see comments]
1996
Metalloproteinases in Multiple Myeloma: Production of Matrix Metalloproteinase-9 (MMP-9), Activation of proMMP-2, and Induction of MMP-1 by Myeloma Cells
1997
Circulating Ki67 positive lymphocytes in multiple myeloma and benign monoclonal gammopathy.
1995
Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia
2000
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process
1998
Improved survival in multiple myeloma and the impact of novel therapies
2007 Standout
Thalidomide in multiple myeloma
2005
A new staging system for multiple myeloma based on the number of S- phase plasma cells
1995
Plasmablastic Morphology—An Independent Prognostic Factor With Clinical and Laboratory Correlates: Eastern Cooperative Oncology Group (ECOG) Myeloma Trial E9486 Report by the ECOG Myeloma Laboratory Group
1998
Bortezomib: Proteasome Inhibition as an Effective Anticancer Therapy
2006
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
2002
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321
2006
Multiple Myeloma
2011 Standout
Genes Expressed in Human Tumor Endothelium
2000 StandoutScience
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
2002 Standout
Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors
1999
Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities
1995
International Staging System for Multiple Myeloma
2005 Standout
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
2006
Autocrine/Paracrine Mechanisms in Human Hematopoiesis
2001
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
2004
Works of TE Witzig being referenced
Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
1999
Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma
1997
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma [see comments]
1993
Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma [see comments]
1996
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma [see comments]
1993
Isolation of a heparin-like anticoagulant from the plasma of a patient with metastatic bladder carcinoma
1989